FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190643530> ?p ?o ?g. }

• W3190643530 endingPage "8" @default.
• W3190643530 startingPage "1" @default.
• W3190643530 abstract "Las complicaciones cardiovasculares son frecuentes en el paciente con la enfermedad coronavírica de 2019 (COVID-19), y se asocian con una mayor mortalidad. Entre las complicaciones cardiovasculares, destacan el síndrome coronario agudo, el daño miocárdico agudo (elevación de troponinas con coronarias normales), arritmias (principalmente fibrilación auricular y arritmias ventriculares), insuficiencia cardiaca, pericarditis/derrame pericárdico y complicaciones tromboembólicas (tromboembolia arterial y venosa, trombosis microvascular, embolia pulmonar, ictus). Por lo tanto, uno de los objetivos del tratamiento del paciente con COVID-19, sobre todo en sus formas más graves, es la prevención de las complicaciones cardiovasculares y trombóticas, lo que sin duda tendría un impacto positivo en el pronóstico de estos pacientes. Fuera de este contexto, los resultados provenientes tanto de ensayos clínicos como de estudios en la práctica clínica muestran que el rivaroxabán es eficaz y seguro en todo el espectro de la enfermedad cardiovascular (fibrilación auricular, enfermedad tromboembólica venosa y enfermedad cardiovascular ateroesclerótica), por lo que podría aportar un valor añadido en la prevención de las complicaciones trombóticas y cardiovasculares durante la pandemia de COVID-19. Cardiovascular complications are common in patients with coronavirus disease 2019 (COVID-19), particularly in severe cases: up to 10-30% of hospitalized COVID-19 patients are affected and there is an associated increase in mortality. Important cardiovascular complications include: acute coronary syndrome; acute myocardial injury (elevated troponin levels with normal coronary arteries); arrhythmias (mainly atrial fibrillation and ventricular arrhythmias); heart failure; pericarditis or pericardial effusion; and thromboembolic events (e.g. arterial and venous thromboembolism, microvascular thrombosis, pulmonary embolism, and stroke). Therefore, one of the aims of treatment for patients with COVID-19, particularly in its most serious forms, is the prevention of cardiovascular and thrombotic complications, which will unquestionably have a positive impact on these patients’ prognoses. In other contexts, data from both clinical trials and real-life studies demonstrate that rivaroxabán is effective and safe across the whole spectrum of cardiovascular disease, including atrial fibrillation, venous thromboembolic disease, and atherosclerotic cardiovascular disease. Consequently, rivaroxabán could provide additional benefits for patients by helping prevent thrombotic and cardiovascular complications during the COVID-19 pandemic." @default.
• W3190643530 created "2021-08-16" @default.
• W3190643530 creator A5015504440 @default.
• W3190643530 creator A5027750311 @default.
• W3190643530 creator A5034486091 @default.
• W3190643530 creator A5036323152 @default.
• W3190643530 creator A5038917850 @default.
• W3190643530 creator A5048552347 @default.
• W3190643530 creator A5052813109 @default.
• W3190643530 creator A5069433292 @default.
• W3190643530 creator A5070929623 @default.
• W3190643530 date "2021-01-01" @default.
• W3190643530 modified "2023-10-17" @default.
• W3190643530 title "Mejorar la prevención de la trombosis y las complicaciones cardiovasculares durante la pandemia de COVID-19" @default.
• W3190643530 cites W1551095964 @default.
• W3190643530 cites W1902881336 @default.
• W3190643530 cites W1994456301 @default.
• W3190643530 cites W2032760665 @default.
• W3190643530 cites W2097854437 @default.
• W3190643530 cites W2117662968 @default.
• W3190643530 cites W2117677020 @default.
• W3190643530 cites W2152623033 @default.
• W3190643530 cites W2225295868 @default.
• W3190643530 cites W2564830433 @default.
• W3190643530 cites W2749380187 @default.
• W3190643530 cites W2763157304 @default.
• W3190643530 cites W2790375504 @default.
• W3190643530 cites W2804559696 @default.
• W3190643530 cites W2805587371 @default.
• W3190643530 cites W2854911625 @default.
• W3190643530 cites W2888169160 @default.
• W3190643530 cites W2919041175 @default.
• W3190643530 cites W2949035540 @default.
• W3190643530 cites W2971121646 @default.
• W3190643530 cites W2973495259 @default.
• W3190643530 cites W2981659669 @default.
• W3190643530 cites W3001118548 @default.
• W3190643530 cites W3004193513 @default.
• W3190643530 cites W3008461878 @default.
• W3190643530 cites W3009207738 @default.
• W3190643530 cites W3009885589 @default.
• W3190643530 cites W3012421327 @default.
• W3190643530 cites W3012551864 @default.
• W3190643530 cites W3013231340 @default.
• W3190643530 cites W3013486442 @default.
• W3190643530 cites W3015863623 @default.
• W3190643530 cites W3016123051 @default.
• W3190643530 cites W3016595631 @default.
• W3190643530 cites W3016613688 @default.
• W3190643530 cites W3016959086 @default.
• W3190643530 cites W3017661324 @default.
• W3190643530 cites W3022060959 @default.
• W3190643530 cites W3022564719 @default.
• W3190643530 cites W3023335388 @default.
• W3190643530 cites W3023873927 @default.
• W3190643530 cites W3027959269 @default.
• W3190643530 cites W3029347845 @default.
• W3190643530 cites W3032541896 @default.
• W3190643530 cites W3033764632 @default.
• W3190643530 cites W3035467903 @default.
• W3190643530 cites W3036408423 @default.
• W3190643530 cites W3036480973 @default.
• W3190643530 cites W3036565291 @default.
• W3190643530 cites W3036961088 @default.
• W3190643530 cites W3041384178 @default.
• W3190643530 cites W3042508286 @default.
• W3190643530 cites W3092247386 @default.
• W3190643530 cites W3165656738 @default.
• W3190643530 doi "https://doi.org/10.1016/s1131-3587(21)00001-7" @default.
• W3190643530 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8320271" @default.
• W3190643530 hasPublicationYear "2021" @default.
• W3190643530 type Work @default.
• W3190643530 sameAs 3190643530 @default.
• W3190643530 citedByCount "0" @default.
• W3190643530 crossrefType "journal-article" @default.
• W3190643530 hasAuthorship W3190643530A5015504440 @default.
• W3190643530 hasAuthorship W3190643530A5027750311 @default.
• W3190643530 hasAuthorship W3190643530A5034486091 @default.
• W3190643530 hasAuthorship W3190643530A5036323152 @default.
• W3190643530 hasAuthorship W3190643530A5038917850 @default.
• W3190643530 hasAuthorship W3190643530A5048552347 @default.
• W3190643530 hasAuthorship W3190643530A5052813109 @default.
• W3190643530 hasAuthorship W3190643530A5069433292 @default.
• W3190643530 hasAuthorship W3190643530A5070929623 @default.
• W3190643530 hasBestOaLocation W31906435301 @default.
• W3190643530 hasConcept C126322002 @default.
• W3190643530 hasConcept C164705383 @default.
• W3190643530 hasConcept C2779161974 @default.
• W3190643530 hasConcept C71924100 @default.
• W3190643530 hasConceptScore W3190643530C126322002 @default.
• W3190643530 hasConceptScore W3190643530C164705383 @default.
• W3190643530 hasConceptScore W3190643530C2779161974 @default.
• W3190643530 hasConceptScore W3190643530C71924100 @default.
• W3190643530 hasLocation W31906435301 @default.
• W3190643530 hasOpenAccess W3190643530 @default.
• W3190643530 hasPrimaryLocation W31906435301 @default.
• W3190643530 hasRelatedWork W1967841144 @default.
• W3190643530 hasRelatedWork W2018480046 @default.

• next